Clinical Trial Search

Primary: Effect of Dapagliflozin, as Compared With Placebo, on Heart Failure Related Health Status Using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Summary…

Primary: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB) — 7…

Primary: Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First — 6.6; 5.9 Events…

Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine

Primary: Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given…

Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) — 0.83; 1.08 ratio: endpoint/baseline (pg/mL)

Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL

Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)…

Primary: Change From Baseline to Week 12 in Log-transformed N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) — -0.098; -0.047; 0.071; 0.057 log-transformed picograms per…

Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio

Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003

Primary: Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization — -2.4; -4.7 mmHG

Primary: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP) — 47.4; 46.4 pg/mL

Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 — 0.8218; 0.9828 Ratio — p=<0.0001

Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…

Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…

Primary: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. — 894; 1009; 690; 797 Events — p=0.0587

Primary: Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or…

Primary: Cardiorespiratory Fitness — 4.1; 4.0; 5.1; 4.5 ml/kg/min

Primary: Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 8.67; 6.86 Patients with event/100 pt-yrs at risk…

Primary: Brachial Artery Flow-mediated Dilation (FMD) — 5; 8 % dilation — p=.17

Primary: Exercise Intolerance — 13.5; 13.3; 13.6; 13.5 ml/kg/min

Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade

Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002

Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL

Primary: Exercise Capacity — 15.5; 15.5; 14.1; 16.6 ml/kg/min — p=<0.001

Primary: Change From Baseline in the CogState Global Cognitive Composite Score (GCCS) — -0.0902; -0.0722 Global Cognitive Composite Score — p=0.7363

Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…

Primary: KCCQ-12 — 47; 39 units on a scale

Primary: Change From Baseline in Treadmill Exercise Time at Maintenance Phase Week 24 — 424.5; 485.0; 89.5; 37.0 Seconds — p=0.0302